section name header

Footnotes

a Tested in PVC containers.

b Tested in polyisoprene infusion pump reservoirs.

c Tested in PVC reservoirs for the Graseby 9000 ambulatory pumps.

d Tested in polyolefin-lined plastic bags.

e Tested with etoposide (BMS) 200 mg/L.

f Tested with etoposide (BMS) 125 mg/L

g Tested with etoposide (BMS) 175 mg/L.

h Tested with etoposide (BMS) 250 mg/L.

i Tested with etoposide (BMS) 350 mg/L.

j Tested with etoposide (BMS) 500 mg/L.

k Tested with etoposide phosphate (BMS) 600 mg/L.

l Tested with etoposide phosphate (BMS) 1.2 g/L.

m Tested with etoposide phosphate (BMS) 2 g/L.

n Tested with ondansetron HCl (GL) 480 mg/L.

o Tested with ondansetron HCl (GL) 960 mg/L.

p Tested with doxorubicin HCl (PHU) 40 mg/L.

q Tested with doxorubicin HCl (PHU) 25 mg/L.

r Tested with doxorubicin HCl (PHU) 35 mg/L.

s Tested with doxorubicin HCl (PHU) 50 mg/L.

t Tested with doxorubicin HCl (PHU) 70 mg/L.

u Tested with doxorubicin HCl (PHU) 100 mg/L.

v Tested with doxorubicin HCl (PHU) 120 mg/L.

w Tested with doxorubicin HCl (PHU) 240 mg/L.

x Tested with doxorubicin HCl (PHU) 400 mg/L.

y Tested with doxorubicin HCl (AD) 400 mg/L.

z Tested with doxorubicin HCl (AD) 800 mg/L.